HALO - Halozyme Therapeutics, Inc.
NEXT EARNINGS:
May 12, 2026
EPS Est: $1.53
|
Rev Est: $357.6M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$76.14
DETAILS
HIGH:
$94.00
LOW:
$56.00
MEDIAN:
$75.00
CONSENSUS:
$76.14
UPSIDE:
8.21%
Market Cap:
8.27B
Volume:
1,306,518
Avg Volume:
2,172,161
52 Week Range:
47.5-82.22
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.98
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
350
IPO Date:
2004-03-16
EPS (TTM):
2.64
P/E Ratio:
25.45
Revenue (TTM):
1.40B
Total Assets:
2.53B
Total Debt:
N/A
Cash & Equiv:
133.82M
Rev Growth (5Y):
39.2%
EPS Growth (5Y):
22.7%
FCF Growth (5Y):
64.9%
ROCE:
34.8%
Debt/Equity:
N/A
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-17 | $-0.24 | $2.15 | -111.2% | $451.8M | $381.7M | +18.4% |
| 2025-11-03 | $1.72 | $1.63 | +5.5% | $354.3M | $446.5M | -20.7% |
| 2025-08-05 | $1.54 | $1.23 | +25.2% | $325.7M | $330.8M | -1.5% |
| 2025-05-06 | $1.11 | $0.95 | +16.8% | $264.9M | $281.0M | -5.7% |
| 2025-02-18 | $1.26 | $1.17 | +7.7% | $298.0M | $285.7M | +4.3% |
| 2024-10-31 | $1.27 | $0.98 | +29.6% | $290.1M | $292.8M | -0.9% |
| 2024-08-06 | $0.91 | $0.76 | +19.7% | $231.4M | $208.9M | +10.7% |
| 2024-05-07 | $0.79 | $0.70 | +12.9% | $195.9M | $199.8M | -2.0% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.40B | 1.02B | 829.25M | 660.12M | 443.31M | 267.59M | 195.99M | 151.86M | 316.61M | 146.69M | 135.06M | 75.33M |
| Net Income | 316.89M | 444.09M | 281.59M | 202.13M | 402.71M | 129.09M | (72.24M) | (80.33M) | 62.97M | (103.02M) | (32.23M) | (68.38M) |
| EPS | 2.64 | 3.50 | 2.13 | 1.48 | 2.86 | 0.95 | -0.50 | -0.56 | 0.46 | -0.81 | -0.25 | -0.56 |
| Total Assets | 2.53B | 2.06B | 1.73B | 1.84B | 1.10B | 579.92M | 565.87M | 440.25M | 519.95M | 261.51M | 181.79M | 165.98M |
| Total Debt | 0 | 1.51B | 1.50B | 1.51B | 876.67M | 397.23M | 402.59M | 126.38M | 202.35M | 216.62M | 49.83M | 49.86M |
| Cash & Equivalents | 133.82M | 115.85M | 118.37M | 234.19M | 118.72M | 147.70M | 120.18M | 57.94M | 168.74M | 66.76M | 43.29M | 61.39M |
| Operating Cash Flow | 651.56M | 479.06M | 388.57M | 240.11M | 299.44M | 55.45M | (85.42M) | (49.50M) | 134.05M | (50.38M) | (37.08M) | (47.52M) |
| Free Cash Flow | 644.59M | 468.37M | 373.28M | 235.30M | 297.98M | 52.95M | (89.46M) | (54.16M) | 132.70M | (53.52M) | (39.44M) | (48.89M) |
| FCF per Share | 5.38 | 3.69 | 2.83 | 1.72 | 2.12 | 0.39 | -0.62 | -0.38 | 0.97 | -0.42 | -0.31 | -0.40 |
| Book Value | 48.81M | 363.82M | 83.81M | 169.80M | 196.95M | 151.05M | 91.77M | 248.89M | 208.37M | (32.48M) | 43.00M | 41.35M |
| Cash & ST Investments | 142.82M | 596.07M | 336.00M | 362.79M | 740.92M | 368.01M | 421.26M | 354.53M | 469.21M | 204.98M | 108.34M | 135.62M |
| ROC Equity | 6.49 | 1.22 | 3.36 | 1.19 | 2.04 | 0.85 | -0.79 | -0.32 | 0.30 | N/A | -0.75 | -1.65 |